- Home
- VIVS vs TOVX Comparison
VIVS vs TOVX Comparison
Compare VIVS & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VIVS | TOVX |
|---|---|---|
| Founded | 2007 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 7.3M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | VIVS | TOVX |
|---|---|---|
| Price | $2.40 | $0.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.0K | ★ 2.6M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $140,000.00 | N/A |
| Revenue This Year | $42.38 | N/A |
| Revenue Next Year | $15.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 35.92 | N/A |
| 52 Week Low | $1.41 | $0.20 |
| 52 Week High | $21.96 | $2.08 |
Technical Indicators
Market Signals| Indicator | VIVS | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 42.24 |
| Support Level | $2.11 | $0.20 |
| Resistance Level | $2.40 | $0.25 |
| Average True Range (ATR) | 0.13 | 0.03 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 54.92 | 32.22 |
Price Performance
Historical ComparisonAbout VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.